• Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust

  • Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust
  1. Home
  2. Medicinal Cannabis Medicines

Medicinal Cannabis Medicines

BOD Australia.png

Bod Australia appoints leading executive as CFO

Finfeed Archived Apr 12, 2021

Cannabis centric healthcare company Bod Australia Limited (ASX: BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021.

BOD Australia.png

Bod Australia achieves quarter-on-quarter sales growth of 61%

Finfeed Archived Apr 01, 2021

Bod Australia (ASX: BDA) achieved record medicinal cannabis sales growth in the March quarter, filling 3789 MediCabilis™ prescriptions.

true blue logo.png

How (and why) companies are mixing Terpenes into Cannabis Distillates

Finfeed Archived May 29, 2020

Cannabis enthusiasts purchase terps and incorporate them into everything from homemade brownies to vape juice. But there’s one industry that’s had surprisingly less of a symbiotic relationship with terpenes than anyone might have expected; namely the cannabis industry.

THC image.JPG

The world in medical cannabis and weed this week

Finfeed Archived May 01, 2020

The final week in April has proven to be a big week in the cannabis sector, with several global milestones expected in May.

Get expert stock analysis direct in your inbox

Join Our
Mailing List

Footer

Portfolio

  • Next Investors
  • Wise Owl
  • Catalyst Hunter
  • Next Biotech
  • Emerge

Support

  • Contact Us
  • Trust Centre
  • How it Works
  • History
  • FAQ
  • Definitions
  • Archived Articles
  • Bottom Drawer Portfolio

Policies

  • Customer Notice
  • Disclosure Policy
  • Financial Services Guide
  • ESG Policy
  • Privacy Policy

Subscribe Next Investors

Daily write ups on small cap stocks we are invested in:


Next Investors

This material has been prepared by S3 Consortium Pty Ltd (trading as StocksDigital). S3 Consortium Pty Ltd is a Corporate Authorised Representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.


© 2026 nextinvestors.com | All rights reserved

Follow Us